VIDEO: Study reaffirms once weekly bortezomib in newly diagnosed multiple myeloma
Click Here to Manage Email Alerts
Healio spoke with Chakra Chaulagain, MD, about a retrospective observational study on prescribing patterns and outcomes of bortezomib in newly diagnosed patients with multiple myeloma presented at ASH Annual Meeting and Exposition.
The study included 2,522 patients aged 18-70 years who were newly diagnosed with multiple myeloma from 2017 to 2022 who received a first-line bortezomib-containing regimen and had at least 6 months of follow-data available and two clinical visits.
Researchers found that prescribing patterns for bortezomib have shifted toward the use of once-weekly bortezomib, but over 30% of patients diagnosed with multiple myeloma in the last 3 years received bortezomib twice a week.
“In terms of progression-free survival and overall survival, there was no difference in the two groups,” Chaulagain, director of the myeloma and amyloidosis program at Cleveland Clinic Florida, told Healio. “So, moving forward, once a week bortezomib should be just good enough, because twice weekly bortezomib we know can cause increased risk for neuropathy and other side effects.”
Reference:
- Hoff FW, et al. Abstract 544. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2023; San Diego.
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts